In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research Summary:
nej.md/437IXTF
ALT The New England Journal of Medicine
Perioperative Durvalumab in Gastric Cancer
A Research Summary based on Janjigian YY et al. | 10.1056/NEJMoa2503701 | Published on June 1, 2025
Visual representations of the patients in the trial and the treatments they were assigned.
Read the full Research Summary at NEJM.org.